Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10668001 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL26132311 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL11615294 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL15349261 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL31339479 | 0.80 | ALDH1A1 (0.65) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL12186574 | 0.78 | ALDH1A1 (0.64) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL2813746 | 0.77 | ALDH1A1 (0.61) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL15349614 | 0.77 | ALDH1A1 (0.61) | ALDH1A1CA1CA2CA4CA5A | |
| SCHEMBL11804342 | 0.75 | ALDH1A1 (0.59) | ALDH1A1FBP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11553876 | 0.74 | ALDH1A1 (0.58) | ALDH1A1CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118136959-A | Application of thiadiazole compound as additive of lithium sulfur battery electrolyte | 吉林省东驰新能源科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| WO-2023187182-A1 | PYRAZOLOPYRAZINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2023-10-05 | — | — | WO | claimed |
| CN-109053634-A | A kind of preparation method of thiazfluron raw medicine | 河北工业大学 | 2018-12-21 | — | — | CN | claimed |
| CN-107501348-A | The preparation method of 2 (4 trifluoromethyl) 6 ferrocenyl imidazo [2,1 b] 1,3,4 thiadiazoles | 张家港贸安贸易有限公司 | 2017-12-22 | — | — | CN | claimed |
| CN-103242308-B | 2-fluoro pyridine derivatives, as well as preparation method and application thereof | UNIV QINGDAO AGRICULTURAL | 2015-07-01 | — | — | CN | claimed |
| CN-103242308-A | 2-fluoro pyridine derivatives, as well as preparation method and application thereof | UNIV QINGDAO AGRICULTURAL | 2013-08-14 | — | — | CN | claimed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673784-A2 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0333317-B1 | Low heat generation type rubber compositions | BRIDGESTONE CORP (JP) | 1994-01-26 | — | — | EP | claimed |
| WO-1993014062-A1 | ANTHELMINTIC β-KETOAMIDES | THE UPJOHN COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
| US-5151468-A | Rubbers for tires | BRIDGESTONE CORPORATION (JP) | 1992-09-29 | — | — | US | claimed |
| EP-0333317-A1 | Low heat generation type rubber compositions | Bridgestone Corporation (JP) | 1989-09-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | ALDH1A1 1971/4885CA1 1599/4885CA2 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.